Novel pharmacophores of connexin43 based on the "rxp" series of Cx43-binding peptides

Circulation Research

Volumn 105, Issue 2, 2009, Pages 176-184

  Verma, Vandana ^a   Larsen, Bjarne Due ^a   Coombs, Wanda ^b   Lin, Xianming ^a   Spagnol, Gaelle ^c   Sorgen, Paul L ^c   Taffet, Steven M ^b   Delmar, Mario ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Arrhythmias; Connexin 43; Gap junctions

Indexed keywords

CONNEXIN 43; HEPTAPEPTIDE; OCTAPEPTIDE; ANTIARRHYTHMIC AGENT; CYCLOPEPTIDE; GJA1 PROTEIN, HUMAN; OLIGOPEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GAP JUNCTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATCH CLAMP; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT; SURFACE PLASMON RESONANCE; ACTION POTENTIAL; ANIMAL; BINDING SITE; CELL JUNCTION; CELL LINE; CHANNEL GATING; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HEART MUSCLE CELL; HEART VENTRICLE; METABOLISM; MOLECULAR GENETICS; NEWBORN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION; PROTEIN MOTIF; SPRAGUE DAWLEY RAT; TIME;

ACTION POTENTIALS; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANIMALS, NEWBORN; ANTI-ARRHYTHMIA AGENTS; BINDING SITES; CELL LINE; COMPUTER-AIDED DESIGN; CONNEXIN 43; DRUG DESIGN; GAP JUNCTIONS; HEART VENTRICLES; HUMANS; ION CHANNEL GATING; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MYOCYTES, CARDIAC; OLIGOPEPTIDES; PATCH-CLAMP TECHNIQUES; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PLASMON RESONANCE; TIME FACTORS; TRANSFECTION;

EID: 68049107032     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.200576     Document Type: Article

References (21)

1. Herve JC, Dhein S. Pharmacology of cardiovascular gap junctions. Adv Cardiol. 2006;42:107-131.
2. Dhein S. Cardiac ischemia and uncoupling: gap junctions in ischemia and infarction. Adv Cardiol. 2006;42:198-212.
3. Srinivas M, Duffy HS, Delmar M, Spray DC. Prospects for pharmacological targeting of gap junction channels. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 4th ed. Philadelphia, Pa: Saunders; 2004:158-167.
4. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy. Circulation. 2003;108: 3157-3163.
5. Haugan K, Petersen JS. Gap junction modifying antiarrhythmic peptides: therapeutic potential in atrial fibrillation. Drugs Future. 2007;32: 245-260.
6. Lewandowski R, Petersen JS, Delmar M. Connexins as potential targets for cardiovascular pharmacology. In: Zipes DP and Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 5th ed. Philadelphia, Pa: Saunders. 2009;205-213
7. Müller A, Schaefer T, Linke W, Tudyka T, Gottwald M, Klaus W, Dhein S. Actions of the antiarrhythmic peptide AAP10 on intercellular coupling. Naunyn Schmiedebergs Arch Pharmacol. 1997;356:76-82.
8. Kjolbye AL, Haugan K, Hennan JK, Petersen JS. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias. Basic Clin Pharmacol Toxicol. 2007;101:215-230.
9. Rossman EI, Liu K, Morgan GA, Swillo RE, Krueger JA, Butera J, Gruver M, Kantrowitz J, Feldman HS, Petersen JS, Haugan K, Gardell SJ, Hennan JK. The gap junction modifier, GAP-134, improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009;329:1127-1133.
10. Axelsen LN, Haugan K, Stahlhut M, Kjølbye AL, Hennan JK, Holstein-Rathlou NH, Petersen JS, Nielsen MS. Increasing gap junctional coupling: a tool for dissecting the role of gap junctions. J Membr Biol. 2007;1:23-35.
11. Dhein S, Polontchouk L, Salameh A, Haefliger JA. Pharmacological modulation and differential regulation of the cardiac gap junction proteins connexin 43 and connexin 40. Biol Cell. 2002;94:409-422.
12. Delmar M, Coombs W, Sorgen P, Duffy HS, Taffet SM. Structural basis for the chemical regulation of connexin43 channels. Cardiovasc Res. 2004 62:268-275.
13. Morley GE, Taffet SM, Delmar M. Intramolecular interactions mediate pH regulation of connexin43 channels. Biophys J. 1996;70: 1294-1302.
14. Ek-Vitorin JF, Calero G, Morley GE, Coombs W, Taffet SM, Delmar M. pH regulation of connexin43: molecular analysis of the gating particle. Biophys J. 1996;71:1273-1284.
15. Seki A, Coombs W, Taffet SM, Delmar M. Loss of electrical communication, but not plaque formation, after mutations in the cytoplasmic loop of connexin43. Heart Rhythm. 2004;1:227-233.
16. Shibayama J, Lewandowski R, Kieken F, Coombs W, Shah S, Sorgen PL, Taffet SM, Delmar M. Identification of a novel peptide that interferes with the chemical regulation of connexin 43. Circ Res. 2006;98: 1365-1372.
17. Lewandowski R, Procida K, Vaidyanathan R, Coombs W, Jalife J, Nielsen MS, Taffet SM, Delmar M. RXP-E: a connexin43-binding peptide that prevents action potential propagation block. Circ Res. 2008; 103:519-526.
18. Che Y, Brooks RB, Marshall RG. Development of small molecules designed to modulate protein-protein Interactions J Comput Aided Mol Des. 2006;20:109-130.
19. Oxford EM, Musa H, Maass K, Coombs W, Taffet SM, Delmar M. Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells. Circ Res. 2007;101:703-711.
20. Lang BD, Delmar M, Coombs W. Surface plasmon resonance as a method to study the kinetics and amplitude of protein-protein binding. In: Dhein S, Mohr FW, Delmar M, eds. Practical Methods in Cardiovasc Res. Heidelberg, Germany: Springer; 2005:936-947.
21. Sorgen PL, Duffy HS, Spray DC, Delmar M. pH-dependent dimerization of the carboxyl terminal domain of Cx43. Biophys J. 2004;87:574-581.